Evaluation of anti-tumor efficacy of injectable Centchroman in mice bearing Ehrlich ascites carcinoma.
Anti-tumor efficacy of Centchroman formulated as niosomes and gel implant was evaluated in Swiss albino mice bearing Ehrlich ascites carcinoma at 10 mg/kg body weight dose given subcutaneously. Median day of death, percentage increase in host life span and changes in body weight were studied. Centchroman significantly (P < 0.05) increased the median day of death both in free and formulated systems. Also, injectable formulations exhibited a significant (P < 0.05) increase in host life span compared to free drug, hence, enhanced anti-tumor efficacy against Ehrlich ascites carcinoma.
Shenoy
B D
BD
Department of Pharmaceutics, College of Pharmaceutical Sciences, Manipal.
Udupa
N
N
Kamath
R
R
Devi
P U
PU
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D001835:Body Weight / Q000187:drug effects; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy*; D002486:Centchroman / Q000627:therapeutic use* / Q000633:toxicity; D002626:Chemistry, Pharmaceutical; D004354:Drug Screening Assays, Antitumor; D051379:Mice
D000970:Antineoplastic Agents; D002486:Centchroman